

DAFTAR PUSTAKA

1. Paterson DL, Bonomo RA. Extended-Spectrum Beta-Lactamases : a Clinical Update. 2005;18(4):657–86.
2. Salah FD, Soubeiga ST, Ouattara AK, Sadji AY, Metuor-Dabire A, Obiri-Yeboah D, et al. Distribution of quinolone resistance gene (qnr) in ESBL-producing *Escherichia coli* and *Klebsiella* spp. in Lomé, Togo. *Antimicrob Resist Infect Control*. 2019;8(1):1–8.
3. Ulfa M. Antibiotik beta-laktam – Magister Administrasi Rumah Sakit [Internet]. [cited 2020 Sep 6]. Available from: <https://mars.umy.ac.id/antibiotik-beta-laktam/>
4. UI DF dan TFK. *Farmakologi dan Terapi*. 6th ed. Gunawan SG, editor. Jakarta: Balai Penerbit Kedokteran Universitas Indonesia; 2016.
5. Bush K. Past and Present Perspectives on β -Lactamases. 2018;1–20.
6. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J Biol Sci*. 2015;22(1):90–101.
7. Chen Y, Liu Z, Zhang Y, Zhang Z, Lei L, Xia Z. Increasing Prevalence of ESBL-Producing Multidrug Resistance *Escherichia coli* From Diseased Pets in Beijing, China From 2012 to 2017. *Front Microbiol*. 2019;10(December):1–12.
8. O'NEILL J. *Tackling Drug-resistance Infections Globally: Final Report and Recommendations The Review on Antimicrobial Resistance*. 2016.
9. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. *Curr Opin Pharmacol*. 2007;7(5):459–69.

10. Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: When and How. *Antibiotics*. 2020;9(2):61.
11. Ho P leung, Yip KS, Chow KH, Lo JYC, Que TL, Yuen K yung. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. *Diagn Microbiol Infect Dis*. 2010;66(1):87–93.
12. Hawkey PM. Prevalence and clonality of extended-spectrum β -lactamases in Asia. *Clin Microbiol Infect*. 2008;14(SUPPL. 1):159–65.
13. Duilla H. Prevalensi Infeksi Oleh Bakteri Penghasil Extended Spectrum Beta Lactamase di RSUP dr. M. Djamil Padang Tahun 2011-2013. *Fak Kedokt Univ Andalas*. 2016;
14. Suri EA. Identifikasi dan Uji Resistansi Bakteri di Kamar Operasi RSUP dr. M. Djamil Padang. *Fak Kedokt Univ Andalas*. 2016;
15. Doi Y, Iovleva A, Bonomo RA. The ecology of extended-spectrum β -lactamases (ESBLs) in the developed world. *J Travel Med*. 2017;24(1):S44–51.
16. Bradford PA. Extended-spectrum β -lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Vol. 14, *Clinical Microbiology Reviews*. American Society for Microbiology (ASM); 2001. p. 933–51.
17. Clasen J, Birkegård AC, Græsbøll K, Folkesson A. Evolution of TEM-type extended-spectrum β -lactamases in *Escherichia coli* by cephalosporins. *J Glob Antimicrob Resist*. 2019 Dec 1;19:32–9.
18. Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: Definition, classification and epidemiology. *Curr Issues Mol Biol*. 2014;17(1):11–22.

19. Salverda MLM, de Visser JAGM, Barlow M. Natural evolution of TEM-1 β -lactamase: Experimental reconstruction and clinical relevance. Vol. 34, FEMS Microbiology Reviews. 2010. p. 1015–36.
20. Cheng WL, Hsueh PR, Lee CC, Li CW, Li MJ, Chang CM, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: Appropriateness of empirical treatment matters. J Microbiol Immunol Infect. 2016 Apr 1;49(2):208–15.
21. Zhao WH, Hu ZQ. Epidemiology and genetics of CTX-M extended-spectrum β -lactamases in Gram-negative bacteria. Vol. 39, Critical Reviews in Microbiology. Informa Healthcare; 2013. p. 79–101.
22. Laudý AE, Róg P, Smolinska-Król K, Ćmiel M, Szooczynska A, Patzer J, et al. Prevalence of ESBL-producing *Pseudomonas aeruginosa* isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. Gonzalez-Bello C, editor. PLoS One. 2017 Jun 1;12(6):e0180121.
23. ESBL (Extended Spectrum beta-Lactamases) and types - Online Biology Notes [Internet]. [cited 2020 Jul 2]. Available from: <https://www.onlinebiologynotes.com/esbl-extended-spectrum-beta-lactamases-and-types/>
24. Jawetz, Melnick, Adelbergs. Mikrobiologi Kedokteran. 27th ed. Jakarta: EGC; 2017.
25. G B, Katzung. Farmakologi Dasar & Klinik. 12th ed. Jakarta: EGC; 2014.
26. Neu HC, Gootz TD. Antimicrobial Chemotherapy. Medical Microbiology. University of Texas Medical Branch at Galveston; 1996.
27. Utami ER. Antibiotika, Resistensi, Dan Rasionalitas Terapi. Vol. 1, El-Hayah. 2011.

28. Rawat D, Nair D. Extended-spectrum β -lactamases in gram negative bacteria. *J Glob Infect Dis.* 2010;2(3):263.
29. Prihatini, Aryati, Hetty. Identifikasi Cepat Mikroorganisme Menggunakan Alat VITEK-2. *Indones J Clin Pathol Med Lab.* 2018;13(3):129.
30. VITEK® 2: Healthcare | bioMérieux [Internet]. [cited 2021 Mar 8]. Available from: <https://www.biomerieux-usa.com/vitek-2>
31. VITEK 2 | Labx [Internet]. [cited 2021 Mar 8]. Available from: <https://www.labx.com/product/vitek2>
32. Penggunaan Alat Vitek® 2 Compact untuk Membuktikan Adanya ESBL pada Peternakan Ayam - Unair News [Internet]. [cited 2021 Mar 8]. Available from: <http://news.unair.ac.id/2020/07/16/penggunaan-alat-vitek-2-compact-untuk-membuktikan-adanya-esbl-pada-peternakan-ayam/>
33. Myat TO, Hannaway RF, Zin KN, Htike WW, Win KK, Crump JA, et al. ESBL- and carbapenemase-producing Enterobacteriaceae in patients with bacteremia, Yangon, Myanmar, 2014. Vol. 23, *Emerging Infectious Diseases.* Centers for Disease Control and Prevention (CDC); 2017. p. 857–9.
34. TIGESIKLIN | PIO Nas [Internet]. [cited 2020 Mar 12]. Available from: <http://pionas.pom.go.id/monografi/tigesiklin>
35. Naelasari DN, Koendhori EB, Dewanti L, Sarassari R, Kuntaman K. The Prevalence of Extended Spectrum Beta-Lactamase (ESBL) Producing Gut Bacterial Flora Among Patients in Dr. Soetomo Hospital and Primary Health Centre in Surabaya. *Folia Medica Indones.* 2018;54(4):256.
36. Ulfa M. Prevalensi Kejadian Extended Spectrum b-Lactamase (ESBL) pada Makanan – MAGISTER ADMINISTRASI RUMAH SAKIT [Internet]. [cited 2021 Jan 5]. Available from: <https://mars.umy.ac.id/prevalensi-kejadian-extended-spectrum-b-lactamase-esbl-pada-makanan/>

37. Kawamura K, Nagano N, Suzuki M, Wachino J, Kimura K, Arakawa Y. ESBL-producing *Escherichia coli* and Its Rapid Rise among Healthy People. *Food Saf.* 2017;5(4):122–50.
38. Zarifi E, Eslami G, Khaledi A, Vakili M, Vazini H, Zandi H. Prevalence of ESBLs in *Acinetobacter baumannii* isolated from intensive care unit (ICU) of Ghaem hospital, Mashhad, Iran. *J Pure Appl Microbiol.* 2017 Jun 1;11(2):811–9.
39. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Vol. 2016, *BioMed Research International*. Hindawi Limited; 2016.
40. ESBL-producing Enterobacteriaceae | HAI | CDC [Internet]. [cited 2021 Jan 6]. Available from: <https://www.cdc.gov/hai/organisms/ESBL.html>
41. Mahamat OO, Lounnas M, Hide M, Dumont Y, Tidjani A, Kamougam K, et al. High prevalence and characterization of extended-spectrum β -lactamase producing Enterobacteriaceae in Chadian hospitals. *BMC Infect Dis.* 2019 Feb 28;19(1):205.
42. Sangare SA, Maiga AI, Guindo I, Maiga A, Camara N, Dicko OA, et al. Prevalence of ESBL-producing enterobacteriaceae isolated from blood cultures in Mali. *J Infect Dev Ctries.* 2016 Oct 1;10(10):1059–64.
43. M HB, Kasturi T, C MR, Indu K. Prevalence of ESBL Production in *Escherichia coli* and *Klebsiella* spp from Different Clinical Samples A Study in a Teaching Hospital in Telangana, India. *IntJCurrMicrobiolAppSci* [Internet]. 2015;4(3):236–43. Available from: <http://www.ijcmas.com/vol-4-3/Hima Bindu M, et al.pdf>
44. *Burkholderia cepacia* in Healthcare Settings | HAI | CDC [Internet]. [cited 2021 Jan 6]. Available from: <https://www.cdc.gov/hai/organisms/bcepaciacia.html>

45. Bhumbra U, Mehta A, Vyas A, Dalal AS. International Journal of Medical Research and Pharmaceutical Sciences ELIZABETHKINGIA MENINGOSEPTICA , AN EMERGING PATHOGEN: A CASE REPORT. 2018;(April).
46. Angelo RGD, Johnson JK, Bork JT, Heil EL, Angelo RGD, Johnson JK, et al. Expert Opinion on Pharmacotherapy Treatment options for extended-spectrum beta- lactamase (ESBL) and AmpC-producing bacteria bacteria. Expert Opin Pharmacother. 2016;17(7):953–67.
47. Chen FL, Wang GC, Teng SO, Ou TY, Yu FL, Lee W Sen. Clinical and epidemiological features of Chryseobacterium indologenes infections: Analysis of 215 cases. J Microbiol Immunol Infect. 2013 Dec 1;46(6):425–32.
48. The Pharmacist's Role in Treating Extended-Spectrum Beta-Lactamase Infections [Internet]. [cited 2021 Jan 10]. Available from: <https://www.uspharmacist.com/article/the-pharmacists-role-in-treating-extended-spectrum-beta-lactamase-infections>
49. Kementerian Kesehatan RI. Formularium Nasional 2019. Menteri Kesehatan RI. 2019;1(1):1–13.
50. Kumar S, Bandyopadhyay M, Mondal S, Pal N, Ghosh T, Bandyopadhyay M, et al. Tigecycline activity against metallo- β -lactamase-producing bacteria. Avicenna J Med [Internet]. 2013 [cited 2021 Jan 10];3(4):92. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841483/>
51. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum β -lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012;40(6):554–6.

52. Elizabethkingia Infections Treatment & Management: Approach Considerations, Prevention [Internet]. [cited 2021 Jan 11]. Available from: <https://emedicine.medscape.com/article/2500046-treatment>
53. Young MM, Lingam G, Tambyah AA. Elizabethkingia Meningoseptica Endogenous Endophthalmitis - A case report. Antimicrob Resist Infect Control. 2014;3(1):1–5.
54. Lan NPH, Hien NH, Le Thi Phuong T, Thanh DP, Thieu NTV, Ngoc DTT, et al. Phenotypic and genotypic characteristics of ESBL and AmpC producing organisms associated with bacteraemia in Ho Chi Minh City, Vietnam. Antimicrob Resist Infect Control. 2017 Oct 16;6(1):105.
55. Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Vol. 4, Frontiers in Microbiology. Frontiers Research Foundation; 2013.
56. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance [Internet]. Vol. 13, Nature Reviews Microbiology. Nature Publishing Group; 2015 [cited 2021 Jan 12]. p. 42–51. Available from: <https://pubmed.ncbi.nlm.nih.gov/25435309/>
57. Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes [Internet]. 2014 Jan 29 [cited 2021 Jan 12];5(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/24637595/>
58. Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Heal [Internet]. 2014 [cited 2021 Jan 12];2014(1):147. Available from: <https://pubmed.ncbi.nlm.nih.gov/25355275/>
59. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence [Internet]. 2013 Feb 15 [cited 2021 Jan 12];4(2):185–91. Available from: www.landesbioscience.com